Moderna announces pipeline updates in first financial results

In its first quarterly financial results as a public company, Moderna announced its first rare disease mRNA program is heading to the clinic.

Moderna Inc. (NASDAQ:MRNA) said Wednesday that it has submitted an IND for mRNA-3704 to treat methylmalonic acidemia, and

Read the full 416 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE